Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts

Kengo Kanai, Mitsuhiro Okano, Tazuko Fujiwara, Shin Kariya, Takenori Haruna, Ryotaro Omichi, Sei ichiro Makihara, Yuji Hirata, Kazunori Nishizaki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods: Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results: 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions: PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.

Original languageEnglish
JournalAllergology International
DOIs
Publication statusAccepted/In press - Dec 14 2015

Fingerprint

Nasal Polyps
Prostaglandin D2
Vascular Endothelial Growth Factor A
Fibroblasts
Eosinophilia
Dinoprostone
Enzyme-Linked Immunosorbent Assay

Keywords

  • CRTH2
  • DP
  • Nasal polyp fibroblast
  • PGD2
  • VEGF

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts. / Kanai, Kengo; Okano, Mitsuhiro; Fujiwara, Tazuko; Kariya, Shin; Haruna, Takenori; Omichi, Ryotaro; Makihara, Sei ichiro; Hirata, Yuji; Nishizaki, Kazunori.

In: Allergology International, 14.12.2015.

Research output: Contribution to journalArticle

Kanai, Kengo ; Okano, Mitsuhiro ; Fujiwara, Tazuko ; Kariya, Shin ; Haruna, Takenori ; Omichi, Ryotaro ; Makihara, Sei ichiro ; Hirata, Yuji ; Nishizaki, Kazunori. / Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts. In: Allergology International. 2015.
@article{7cd107f43a194d60a02b47875c2d5b25,
title = "Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts",
abstract = "Background: Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods: Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results: 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions: PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.",
keywords = "CRTH2, DP, Nasal polyp fibroblast, PGD2, VEGF",
author = "Kengo Kanai and Mitsuhiro Okano and Tazuko Fujiwara and Shin Kariya and Takenori Haruna and Ryotaro Omichi and Makihara, {Sei ichiro} and Yuji Hirata and Kazunori Nishizaki",
year = "2015",
month = "12",
day = "14",
doi = "10.1016/j.alit.2016.03.003",
language = "English",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",

}

TY - JOUR

T1 - Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts

AU - Kanai, Kengo

AU - Okano, Mitsuhiro

AU - Fujiwara, Tazuko

AU - Kariya, Shin

AU - Haruna, Takenori

AU - Omichi, Ryotaro

AU - Makihara, Sei ichiro

AU - Hirata, Yuji

AU - Nishizaki, Kazunori

PY - 2015/12/14

Y1 - 2015/12/14

N2 - Background: Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods: Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results: 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions: PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.

AB - Background: Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods: Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results: 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions: PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.

KW - CRTH2

KW - DP

KW - Nasal polyp fibroblast

KW - PGD2

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84963641643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963641643&partnerID=8YFLogxK

U2 - 10.1016/j.alit.2016.03.003

DO - 10.1016/j.alit.2016.03.003

M3 - Article

C2 - 27091669

AN - SCOPUS:84963641643

JO - Allergology International

JF - Allergology International

SN - 1323-8930

ER -